Brief: Xspray Pharma's Drug Candidate XS004 Gets Granted Orphan Drug For Treatment Of Acute Lymphoblastic Leukemia

Xspray Pharma publ AB

30/11/2022 15:05

Nov 30 (Reuters) - XSpray Pharma AB (publ)  XSPRAY.ST :
    * DRUG CANDIDATE XS004 GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR THE TREATMENT OF ACUTE
LYMPHOBLASTIC LEUKEMIA
    * FDA DECISION IS BASED ON POTENTIAL THAT XS004 MAY BE CLINICALLY SUPERIOR TO OTHER DRUGS
ALREADY
APPROVED FOR SAME INDICATION

Source text for Eikon:  ID:nMFN8NV65Z 
Further company coverage:  XSPRAY.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))